{kanada_flagge}Predictmedix AI Inc’s (CSE: PMED; OTCQB: PMEDF; FRA:3QP) data trove is growing rapidly. The company says 200,000 individual scans have now been performed using the company’s AI-powered Safe Entry Stations. These have included various vital signs such as body temperature, heart rate, respiratory rate, body weight, HRV, fatigue and impairment.
Summary: Canadian company Predictmedix AI sees an opportunity for its technology to gain traction, particularly in the populous countries of India and Indonesia. Safe Entry Stations are more readily accepted there than would presumably be the case in Western industrialized nations. However, the company’s ambitions go much further. AI-based diagnostics are likely to play a significant role in the future of healthcare globally. This makes the treasure trove of data that Predictmedix is collecting all the more valuable.
Predictmedix AI Inc’s (CSE: PMED; OTCQB: PMEDF; FRA:3QP) data trove is growing rapidly. The company says 200,000 individual scans have now been performed using the company’s AI-powered Safe Entry Stations. These have included various vital signs such as body temperature, heart rate, respiratory rate, body weight, HRV, fatigue and impairment.
The broader the data set, the more effective machine learning can be in improving the accuracy of diagnosis. The company’s diverse data set for Safe Entry includes different skin colors, age groups, and genders from different geographic regions. Consequently, the generalized AI models for various vital signs are universally applicable across all ethnicities. To address privacy concerns, Predictmedix emphasizes its strict privacy policies that ensure no data is stored without the consent of individuals. All data collection is based on the explicit consent of the data subjects.
Dr. Rahul Kushwah, COO of Predictmedix AI commented, “The data collected from Safe Entry scans has significantly enhanced our machine learning capabilities, enabling us to provide more accurate and reliable solutions to the healthcare industry. This rich data set provides an unprecedented opportunity to gain deeper insights into various health indicators and trends, enabling a more comprehensive understanding of human health. In addition, this rich trove of data serves as a powerful resource for medical research and innovation, enabling experts to explore new avenues for disease prevention, early detection and personalized health solutions.”
Safe Entry is based on advanced artificial intelligence algorithms. The stations have been proven in triage functions in hospitals and other settings. The state-of-the-art technology quickly and accurately identifies potential health risks, including infectious disease symptoms, ensuring the well-being of individuals and communities.
Summary: Canadian company Predictmedix AI sees an opportunity for its technology to gain traction, particularly in the populous countries of India and Indonesia. Safe Entry Stations are more readily accepted there than would presumably be the case in Western industrialized nations. However, the company’s ambitions go much further. AI-based diagnostics are likely to play a significant role in the future of healthcare globally. This makes the treasure trove of data that Predictmedix is collecting all the more valuable.
Disclaimer: GOLDINVEST Consulting GmbH publishes comments, analyses and news on https://goldinvest.de. These contents are exclusively for the information of the readers and do not represent a call to action, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. Furthermore, they are in no way a substitute for individual expert investment advice and do not constitute an offer to sell the discussed stock(s) or a solicitation to buy or sell securities. It is expressly not a financial analysis, but a promotional/journalistic text. Readers who make investment decisions or execute transactions on the basis of the information provided here do so exclusively at their own risk. There is no contractual relationship between GOLDINVEST Consulting GmbH and its readers or the users of its offers, because our information refers only to the company, but not to the investment decision of the reader.
The acquisition of securities is associated with high risks, which can lead to a total loss of the invested capital. The information published by GOLDINVEST Consulting GmbH and its authors is based on careful research. Nevertheless, any liability for financial losses or the content guarantee for topicality, correctness, adequacy and completeness of the articles offered here is expressly excluded. Please also note our terms of use.
Pursuant to §34b WpHG and §48f Abs. 5 BörseG (Austria) we point out that GOLDINVEST Consulting GmbH and/or partners, principals or employees of GOLDINVEST Consulting GmbH hold shares in Predictmedix and therefore a conflict of interest exists. GOLDINVEST Consulting GmbH also reserves the right to buy or sell shares of the company at any time. Furthermore, GOLDINVEST Consulting GmbH is remunerated by Predictmedix for reporting on the company. This is another clear conflict of interest.
